Trial · NCT00001521
Outcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Adult Height Relative to General Population | Followed to attainment of adult height, average of 11 years from date of randomization | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Adult Height Relative to Mid-parental Height | Followed to attainment of adult height, average of 11 years from date of randomization | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Predicted Adult Height | At date of randomization and at pubertal onset (average of seven years from date of randomization) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Predicted Adult Height Change | From date of randomization to pubertal onset visit (which on average was seven years), pubertal onset to final visit (average was 4 years), and date of randomization to final visit (average of 11 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Number of Years Bone Age Remained Unchanged | From date of randomization to pubertal onset visit (which on average was seven years) and pubertal onset to final visit (average was 4 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Years | MEAN |
| SECONDARY | Change in Body Mass Index (BMI) | From date of randomization to pubertal onset visit (which on average was seven years) and pubertal onset to final visit (average was 4 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Body Mass Index (BMI) | Pubertal onset visit (average of seven years from date of randomization) and at final visit (average of 11 years from date of randomization) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Average Annual Growth Velocity | From date of randomization to pubertal onset visit (which on average was seven years) and pubertal onset to final visit (average was 4 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Standard Deviation Score (SDS) units | MEAN |
| SECONDARY | Dose of Oral Hydrocortisone | At date of randomization, pubertal onset (average of seven years from date of randomization), and at final visit (average of 11 years from date of randomization) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | mg/m2 /day | MEAN |
| SECONDARY | Average Daily Dose of Oral Hydrocortisone | From date of randomization to pubertal onset visit (which on average was seven years), pubertal onset to final visit (average was 4 years), and date of randomization to final visit (average of 11 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | mg/m2 /day | MEAN |
| SECONDARY | Percent of Visits With 17-hydroxyprogesterone in the Optimal Range (<1,200 ng/dL) | From date of randomization to pubertal onset visit (which on average was seven years) and pubertal onset to final visit (average was 4 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Percentage of visits | MEDIAN |
| SECONDARY | Percent of Visits With Androstenedione in Normal Range | From date of randomization to pubertal onset visit (which on average was seven years) and pubertal onset to final visit (average was 4 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Percentage of visits | MEDIAN |
| SECONDARY | Average Testosterone | From date of randomization to pubertal onset visit (which on average was seven years) and pubertal onset to final visit (average was 4 years) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | ng/dL | MEDIAN |
| SECONDARY | Number of Participants With Onset of Early Central Puberty | Measured from date of randomization to onset of early central puberty | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Average Age at Menarche | Followed from date of randomization to onset of menarche | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Years | MEAN |
| SECONDARY | Number of Female Participants With Normal Menstrual Cyclicity at Final Visit | Measured at single time point at final visit, average of 11 years from date of randomization | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) > 2.5 | Final visit, average of 11 years from date of randomization | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Average (Median) Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) | Measured at single time point at final visit, average of 11 years from date of randomization | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Units on a scale | MEDIAN |
| SECONDARY | Number of Male Participants With Testicular Adrenal Rest Tumors (TART) | Pubertal onset visit (average of seven years from date of randomization) and at final visit (average of 11 years from date of randomization) | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Anterior Posterior Spine Bone Mineral Density (BMD) at Final Visit | Final visit, average of 11 years from date of randomization | Modified intention-to-treat population, includes patients who were reassigned from investigational to standard therapy due to drug intolerance. | Z Scores | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00001521/outcomes